Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JZP898 |
Trade Name | |
Synonyms | JZP-898|JZP 898|WTX-613|WTX613 |
Drug Descriptions |
JZP898 comprises IFNalpha2b linked to half-life extension domains by protease-sensitive linkers that are cleaved to in the presence of proteases in the tumor microenvironment to release IFNalpha2b, potentially inducing IFNalpha signaling and increased anti-tumor immune response (Cancer Res (2023) 83 (7_Supplement):1817). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
JZP898 | JZP898 | 0 | 1 |
JZP898 + Pembrolizumab | JZP898 Pembrolizumab | 0 | 1 |